Clinical Trial Details
— Status: Recruiting
Administrative data
| NCT number |
NCT03682458 |
| Other study ID # |
CGM-02 |
| Secondary ID |
|
| Status |
Recruiting |
| Phase |
|
| First received |
|
| Last updated |
|
| Start date |
December 1, 2019 |
| Est. completion date |
October 1, 2025 |
Study information
| Verified date |
April 2022 |
| Source |
Neuromed IRCCS |
| Contact |
n/a |
| Is FDA regulated |
No |
| Health authority |
|
| Study type |
Observational
|
Clinical Trial Summary
Neurological and neurodegenerative diseases have a major impact in families and in the
national health service due to the lack in many cases of effective and long-lasting
therapies. The lack of these therapeutic strategies is due in large part to the difficulty of
modeling these pathologies in vitro. In fact, the impossibility of being able to cultivate
human neurons in vitro has forced the use of animal cell models that do not adequately
recapitulate the complexity of these human pathologies. For this reason it is necessary to
proceed with the development of in vitro models of human origin that reproduce the molecular
and biochemical characteristics of these diseases.
The discovery of cellular reprogramming allowed the generation of pluripotent stem cells from
the conversion of somatic cells taken from adult individuals.
The proposing group already has great experience in generating iPS cells by reprogramming and
in differentiating them into neurons and glias useful for neurological disease cellular
studies. As an example, Dr. Broccoli's group has generated iPS cells from patients with
Parkinson's disease and mutations in the OPA1 gene. The study of neurons differentiated by
these iPS cells allowed to identify mitochondrial defects at the base of neuronal
dysfunctions and to identify for the first time how the degeneration of dopaminergic neurons
also depends on a moving mode of cell death called necroptosis.
The investigators therefore propose to establish lines of iPS cells from patients with
genetic mutations responsible for neurological and neurodegenerative diseases to generate
neuronal and glial models in vitro for the study of pathological mechanisms and the
validation of new future experimental therapies.
Description:
1. INTRODUCTION Neurological and neurodegenerative diseases have a major impact in families
and in the national health service due to the lack in many cases of effective and
long-lasting therapies. The lack of these therapeutic strategies is due in large part to
the difficulty of modeling these pathologies in vitro. In fact, the impossibility of
being able to cultivate human neurons in vitro has forced the use of animal cell models
that do not adequately recapitulate the complexity of these human pathologies. For this
reason it is necessary to proceed with the development of in vitro models of human
origin that reproduce the molecular and biochemical characteristics of these diseases.
The discovery of cellular reprogramming allowed the generation of pluripotent stem cells
from the conversion of somatic cells taken from adult individuals. This technology is
based on the expression of the 4 genes OCT4, SOX2, KLF4 and c-MYC that synergistically
are sufficient to convert somatic cells into induced stem cells called iPS (1,2). For
this technology Prof. S. Yamanaka from the University of Kyoto was awarded the Nobel
Prize for Medicine in 2012 (3). Human iPS-induced stem cells can be maintained in vitro
in a stable manner over time and then be differentiated into any specialized cell
including neurons and glial cells. In this way, therefore, it is possible to generate
human neurons from adult individuals suffering from neurological pathologies, allowing
the study of pathophysiological mechanisms in cells affected by these diseases. Research
in recent years has established many reliable protocols to differentiate human iPS cells
into different subtypes of neurons (glutamatergics, GABAergics, dopaminergics),
astrocytes, oligodendrocytes and microglia (4-6). Thanks to these procedures it was
possible to generate neuronal and glial models of many neurological diseases by creating
very useful systems for studying pathological processes and identifying new therapeutic
targets for some genetic forms of Alzheimer's, Parkinson's and autism (7-9).
The proposing group already has great experience in generating iPS cells by
reprogramming and in differentiating them into neurons and glias useful for neurological
disease cellular studies. As an example, Dr. Broccoli's group has generated iPS cells
from patients with Parkinson's disease and mutations in the OPA1 gene (8). The study of
neurons differentiated by these iPS cells allowed to identify mitochondrial defects at
the base of neuronal dysfunctions and to identify for the first time how the
degeneration of dopaminergic neurons also depends on a moving mode of cell death called
necroptosis (8).
The investigators therefore propose to establish lines of iPS cells from patients with
genetic mutations responsible for neurological and neurodegenerative diseases to
generate neuronal and glial models in vitro for the study of pathological mechanisms and
the validation of new future experimental therapies.
2. PURPOSE AND DRAWING OF THE STUDY The aim of this study is to generate iPS-induced stem
cell lines from patients with neurological and neurodegenerative diseases to
differentiate into neurons and glial cells to study the pathological cellular and
molecular processes of these diseases. These in vitro cultures will also be used to
validate molecules or experimental therapeutic approaches. IPS cells will be generated
by the reprogramming of isolated 10-mL cells of peripheral venous blood.
The study therefore involves taking 10 ml of peripheral blood from
1. Subjects carrying genetic mutations that condition the development of neurological and /
or neurodegenerative diseases.
2. Relatives or family control non-carriers of genetic mutations conditioning the
development of metabolic and / or neurodegenerative diseases (healthy donors).
3. EXPERIMENTAL PHASE
1. Following a Neurological visit, a Neurological Consultation is requested by the
Neurologist.
2. Genetic Counseling is performed and the molecular test to be performed is identified.
Classical diagnostic paths are applied according to specific national guidelines for
each pathology (SIGU: http://www.sigu.net/show/attivita/5/1/LINEE%20GUIDA%20SIGU) that
indicate the analysis of the most suitable to analyze and above all more frequently
involved.
3. A blood sample is taken after signing an informed consent form (informed consent
Neuromed version 12.02.2015) for the diagnostic study. Approximately 10 milliliters of
blood will be taken and subsequently a part will be fractionated in serum and
lymphocytes which will be stored at -80 ° C.
4. Molecular analyzes are carried out at the Center for Molecular Genetics of the IRCCS INM
Neuromed Institute through NGS or Sanger Sequencing, Multiplex Ligation-dependent Probe
Amplification (MLPA) and Microsatellites.
5. If the molecular diagnosis has identified a gene and / or a variant of interest
compatible with the clinical phenotype, or has identified a variant with uncertain
clinical significance (VoUS), the real scientific importance of generating the patient's
iPS stem cells is evaluated in object
6. If the possibility of generating such cells is positively evaluated, during
consultation, at the same time as the withdrawal of the report, the patient is asked for
his consent (informed consent Neuromed version 12.02.2015) to participate in this
research protocol. A peripheral blood sample of 10 ml is performed.
7. Blood samples in tubes with EDTA as anticoagulant are sent by express courier to the
laboratory of Dr. Vania Broccoli at the San Raffaele Hospital (OSR) where the
mononuclear cells of the blood will be reprogrammed in iPS stem cells.
8. Part of the iPS stem cells generated in OSR will be sent to the NEUROMED to confirm the
pathological mutation and the correct cell genetic
9. iPS stem cells will be differentiated into neurons and glia for the study of the
pathological mechanisms underlying neuropathology.
10. iPS stem cell aliquots will be cryopreserved in liquid nitrogen both in OSR and in
NEUROMED to ensure the maintenance of the lines that will be maintained until the end of
the study.
4. MATERIALS AND METHODS Reprogramming of peripheral blood mononuclear cells Once the 10 ml
of peripheral venous blood is obtained, mononuclear cells (PBMCs) will be isolated and
reprogrammed using the Sendai RNA virus, which expresses the 4 genes SOX2, OCT4, KLF4 and
c-MYC without integrating in the cell genome. This operation will be performed in sterile BL2
rooms available at the laboratory of Dr. Vania Broccoli at the Neuroscience Division of the
San Raffaele Hospital in Milan.
Then the PBMCs will be then plated on a fibroblast mat in sterile 10 mm Petri dishes with a
culture medium enriched with the cytokine bFGF (4ng / ml) (8). In these culture conditions,
the first iPS reprogrammed stem cell clones will be visible after approximately 30 days. At
this point, the individual clones will be isolated and grown to amplify the number of cells
and establish proliferating lines. The progeny of the single clones will be studied to verify
the correct reprogramming in pluripotent stem cells through: 1) activation of marker genes of
the state of pluripotent staminality (Nanog, Sox2, Oct4, SEEA4), capacity of in vitro
differentiation in the somatic cells of the three sheets embryonic endoderm, mesoderm and
ectoderm, minimal contamination of differentiated cells in the culture. Once the induced
pluripotent stem cell generation (iPS) has been validated, the cells will be used to be
differentiated into different neuronal and glial types for experiments aimed at understanding
and describing the pathogenetic mechanisms of the subject's study diseases. For the
generation of neurons will be followed the protocol developed by Shi and colleagues (5) that
uses retinoic acid and TGFbeta / BMP proteins inhibitors to direct the neuroectodermal
differentiation. This procedure has already been validated and used in our laboratories
demonstrating the differentiation of iPS stem cells into mature and functioning neurons (10)
(Figure 1).
Once the processes of differentiation with iPS stem cells have been established, the
investigators will proceed with the analysis of the phenotype in the patients' cells with
respect to controls derived from healthy controls. In particular, with regard to the analyzes
in neurons, survival parameters will be investigated, neuronal activity through
electrophysiological recordings, mitochondrial morphology and metabolism, endoplasmic
reticulum stress, and synapse formation and functioning. For glial cells the levels of
inflammation including the activity of TNF-alpha, IL-1beta, IL-4, IL-6 and NOS proteins will
be analyzed. Along with these studies, a genomic analysis will be carried out by comparing
the gene expression profiles of neurons and glial cells. The analysis will be done for
RNA-Seq, a "next-generation sequencing" technique that allows to analyze the expression
levels of all genes in the genome. The genes thus identified will be validated with real-time
PCR analysis and their functioning will be investigated in neurons and cells derived from the
patient's cells.
5. STATISTICS For the study of pathological processes 6 lines of iPS cells will be derived
from each patient and healthy individual. The investigators anticipate from our previous
experience that the comparison between this number of lines between patient and healthy donor
is more than sufficient to have statistical significance for the different in vitro
experiments that will be performed. In case it will be possible to generate new lines of iPS
cells from the same patient in the unlikely event it was necessary.
6. ETHICAL ASPECTS The procedures reported in the study concerning conducting, conducting and
documentation are designed to ensure that the ethical principles set forth in the Helsinki
Declaration and its revisions are upheld. The study will be conducted taking into account
regulatory requirements and legal obligations. In particular, the normative reference is
represented by the DL n.211, 24/06/2003 and DM 17/12/2004 on non-profit studies. Furthermore,
before enrollment, all potentially eligible patients will receive complete and comprehensive
information on the study. In order to be enrolled it will be necessary that the patients
consent to the participation in the study and processing of personal data, according to the
law 196/03 on the protection of persons and the processing of personal data. The informed
consent previously approved by the ethics committee will be used.
7. FINAL OBJECTIVES This program aims to identify the sub-cellular processes altered exactly
in human cells (neurons and i) affected by the neuropathologies in question. Furthermore,
this study will also allow us to integrate molecular data with the aim of identifying genes
whose specific alterations may underlie these cellular dysfunctions. The ultimate aim of this
experimental program is to identify the alteration of specific molecular mechanisms
underlying these diseases. These new knowledge will be essential to think about the
development of new translational strategies based on pharmacological approaches or gene
therapy. This is of great importance since the diseases in question are orphans of effective
treatment and limited to exclusively symptomatic treatments.
8. PROJECT COSTS Molecular diagnostics is performed routinely at the Molecular Genetics
Center of IRCCS Neuromed. There are no additional costs as the analyzes are part of
diagnostic procedures carried out in agreement with the NHS.
IPS generation is performed by IRCCS San Raffaele. The costs for the development of these
lines are therefore completely dependent on them.
